Perrigo Company plc Increase (Decrease) in Other Accrued Liabilities
Perrigo Company plc (PRGO) reported Increase (Decrease) in Other Accrued Liabilities of $44.40 million for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2026-08-05
- Perrigo Company plc increase (decrease) in other accrued liabilities for the quarter ending 2026-06-27 was $52.10M, a 94.40% increase year-over-year.
- Perrigo Company plc increase (decrease) in other accrued liabilities for the quarter ending 2026-03-28 was -$7.70M.
- Perrigo Company plc increase (decrease) in other accrued liabilities for the quarter ending 2025-12-31 was -$18.80M.
- Perrigo Company plc increase (decrease) in other accrued liabilities for the quarter ending 2025-09-27 was $31.60M, a 19.59% decline year-over-year.
- Perrigo Company plc increase (decrease) in other accrued liabilities for fiscal 2025 was -$16.50M.
- Perrigo Company plc increase (decrease) in other accrued liabilities for fiscal 2024 was -$1.30M, a 119.70% decline from fiscal 2023.
- Perrigo Company plc increase (decrease) in other accrued liabilities for fiscal 2023 was $6.60M, a 34.65% decline from fiscal 2022.
- Perrigo Company plc increase (decrease) in other accrued liabilities for fiscal 2022 was $10.10M.
| Period end | Increase (Decrease) in Other Accrued Liabilities 3 month | Increase (Decrease) in Other Accrued Liabilities 6 month | Increase (Decrease) in Other Accrued Liabilities 9 month | Increase (Decrease) in Other Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-27 | $52.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $44.40M 10-Q · filed 2026-08-05 | $25.60M derived: sum of 3 quarters · filed 2026-08-05 | $57.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | -$7.70M 10-Q · filed 2026-05-06 | -$26.50M derived: sum of 2 quarters · filed 2026-05-06 | $5.10M derived: sum of 3 quarters · filed 2026-05-06 | $31.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$18.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $12.80M derived: sum of 2 quarters · filed 2026-02-26 | $39.60M derived: sum of 3 quarters · filed 2026-08-05 | -$16.50M 10-K · filed 2026-02-26 |
| 2025-09-27 | $31.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $58.40M derived: sum of 2 quarters · filed 2026-08-05 | $2.30M 10-Q · filed 2025-11-05 | -$21.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | $26.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$29.30M 10-Q · filed 2026-08-05 | -$53.00M derived: sum of 3 quarters · filed 2026-08-05 | -$13.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-29 | -$56.10M 10-Q · filed 2026-05-06 | -$79.80M derived: sum of 2 quarters · filed 2026-05-06 | -$40.50M derived: sum of 3 quarters · filed 2026-05-06 | -$88.00M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$23.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $15.60M derived: sum of 2 quarters · filed 2026-02-26 | -$31.90M derived: sum of 3 quarters · filed 2026-02-26 | -$1.30M 10-K · filed 2026-02-26 |
| 2024-09-28 | $39.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$8.20M derived: sum of 2 quarters · filed 2025-11-05 | $22.40M 10-Q · filed 2025-11-05 | $15.80M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-29 | -$47.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$16.90M 10-Q · filed 2025-08-06 | -$23.50M derived: sum of 3 quarters · filed 2026-02-26 | -$10.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-30 | $30.60M 10-Q · filed 2025-05-07 | $24.00M derived: sum of 2 quarters · filed 2026-02-26 | $37.50M derived: sum of 3 quarters · filed 2026-02-26 | |
| 2023-12-31 | -$6.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.90M derived: sum of 2 quarters · filed 2026-02-26 | $6.60M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $13.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $13.20M 10-Q · filed 2024-11-06 | ||
| 2023-07-01 | -$300.00K 10-Q · filed 2024-08-02 | |||
| 2022-12-31 | $10.10M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |